LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L) Tuesday announced positive
results from the NIAGARA Phase III trial of Imfinzi in combination with
chemotherapy in patients with muscle-invasive bladder cancer (MIBC).

In the study, MIBC patients were treated with a combination of Imfinzi and
neoadjuvant chemotherapy before cystectomy followed by Imfinzi as adjuvant
monotherapy.

Results from the study showed that Imfinzi in combination with chemotherapy
demonstrated a statistically significant and clinically meaningful improvement
in the primary endpoint of event-free survival (EFS) and the key secondary
endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients
with MIBC. Further, Imfinzi was generally well-tolerated and no new safety
concerns were observed in either the neoadjuvant or adjuvant setting.

Imfinzi is already approved to treat various cancers including non-small cell
lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer,
hepatocellular carcinoma (HCC), and endometrial cancer.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX